Natco Pharma launches generic Carboplatin Injection in U.S. market

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.2%Reaction day

₹785.85

prior close

₹791.65

announcement price

In-mkt

timing

Nifty Smallcap 250market-1.1%+3.3% vs market

Pharmaceuticals peers, median of 172sector-1.6%+3.8% vs sector

On the reaction day the stock moved 3.3 pts more than Nifty Smallcap 250 and 3.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+1.7

15m

+1.8

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.2-1.1+3.3-1.6+3.8

Next day

-0.2-3.4+3.1-3.5+3.2

+0.0-4.4+4.4-3.8+3.8

+0.6-7.1+7.7-5.3+5.8

+0.9-6.1+7.0-4.1+5.1

+1.5-4.0+5.5-2.4+3.9

+0.1-3.0+3.2-1.3+1.5

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Natco Pharma has launched Carboplatin Injection, a generic version of Paraplatin, in the U.S. market through its subsidiary NATCO Pharma USA LLC. The product is used to treat advanced ovarian carcinoma and addresses a critical shortage in the U.S. The drug had estimated U.S. sales of USD 27.8 million for 12 months ending June 2026. Manufacturing is in collaboration with Teyro Labs based in Chennai.

Likely market impact

New revenue opportunity in the U.S. market addressing a critical drug shortage; positive for U.S. business growth.